BioXcel Therapeutics, Inc. Liabilities, Fair Value Adjustment
BioXcel Therapeutics, Inc. (BTAI) reported Liabilities, Fair Value Adjustment of -$438.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-22.
Discontinued › Notes › Fair Value Disclosures
us-gaap:LiabilitiesFairValueAdjustment · last filed 2024-03-22
- BioXcel Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-12-31 was -$122.00K, a 126.99% decline year-over-year.
- BioXcel Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-09-30 was $1.00K.
- BioXcel Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-06-30 was -$548.00K.
- BioXcel Therapeutics, Inc. liabilities, fair value adjustment for the quarter ending 2023-03-31 was $231.00K.
- BioXcel Therapeutics, Inc. liabilities, fair value adjustment for fiscal 2023 was -$438.00K, a 212.60% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. liabilities, fair value adjustment for fiscal 2022 was $389.00K.
| Period end | Liabilities, Fair Value Adjustment 3 month | Liabilities, Fair Value Adjustment 6 month | Liabilities, Fair Value Adjustment 9 month | Liabilities, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$121.00K derived: sum of 2 quarters · filed 2024-03-22 | -$669.00K derived: sum of 3 quarters · filed 2024-03-22 | -$438.00K 10-K · filed 2024-03-22 |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$547.00K derived: sum of 2 quarters · filed 2023-11-14 | -$316.00K 10-Q · filed 2023-11-14 | $136.00K derived: sum of 4 quarters · filed 2024-03-22 |
| 2023-06-30 | -$548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$317.00K 10-Q · filed 2023-08-14 | $135.00K derived: sum of 3 quarters · filed 2024-03-22 | |
| 2023-03-31 | $231.00K 10-Q · filed 2023-05-09 | $683.00K derived: sum of 2 quarters · filed 2024-03-22 | ||
| 2022-12-31 | $452.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $389.00K 10-K · filed 2024-03-22 | ||
| 2022-09-30 | -$63.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |